The Role of the ROMA Algorithm in Enhancing Assessment Accuracy
The ROMA algorithm combines CA-125, HE4 biomarkers and menopausal status into a risk score that may improve ovarian health assessment accuracy compared to single biomarker testing alone.
The ROMA algorithm represents a sophisticated computational approach that combines multiple biomarkers to improve risk assessment accuracy in ovarian health evaluation. This mathematical model integrates tumour marker levels with menopausal status to provide healthcare professionals with enhanced analytical support, particularly when evaluating pelvic masses.
Understanding how this algorithm functions can help individuals make informed decisions about their health screening options, particularly when discussing ovarian health concerns with healthcare professionals in London and across the UK.
What is the ROMA Algorithm?
Practical Definition: The Risk of Ovarian Malignancy Algorithm (ROMA) is a mathematical formula that calculates risk scores by combining CA-125 and HE4 biomarker levels with a patient’s menopausal status. This computational approach may provide more reliable assessment data than individual tumour markers alone.
The algorithm generates numerical scores that healthcare professionals can interpret alongside clinical examination findings and imaging results. Rather than relying on single biomarker values, ROMA creates a comprehensive risk assessment that accounts for the complex interplay between different biological indicators.
Practical Insight: ROMA doesn’t replace clinical judgement but rather provides additional analytical support that can enhance healthcare decision-making processes. For broader context on how multi-marker approaches differ from single-test strategies, see our guide to the application and accuracy of the ROMA algorithm.
How the ROMA Algorithm Works
Biomarker Integration Process
The ROMA calculation incorporates two key tumour markers:
- CA-125: A protein that may be elevated in various conditions affecting the ovaries, uterus, and other pelvic organs
- HE4: A protein that can sometimes indicate changes in ovarian tissue
The combination of these two markers is what makes ROMA more informative than either alone — our article on CA-125 vs HE4 and why the combined approach is more reliable explains the clinical reasoning behind this dual-marker strategy.
The algorithm applies different mathematical weightings based on menopausal status, recognising that biomarker interpretation varies significantly between pre- and post-menopausal individuals. For a detailed walkthrough of the personalised score calculations, see our article on how the ROMA algorithm calculates personalised ovarian health risk scores.
Calculation Methodology
| Algorithm Component | Pre-Menopausal Formula | Post-Menopausal Formula |
|---|---|---|
| Predictive Index (PI) | −12.0 + 2.38 × ln(HE4) + 0.0626 × ln(CA-125) | −8.09 + 1.04 × ln(HE4) + 0.732 × ln(CA-125) |
| ROMA Score | exp(PI) / [1 + exp(PI)] × 100 | exp(PI) / [1 + exp(PI)] × 100 |
| Low Risk Threshold | <11.4% | <29.9% |
Practical Insight: The algorithm’s strength lies in its ability to process complex data relationships that might be challenging to assess through individual biomarker evaluation alone.
Clinical Applications and Benefits
Enhanced Assessment Accuracy
Research suggests that ROMA algorithm applications may improve assessment sensitivity compared to single biomarker assessments. Studies have indicated that combining multiple markers through mathematical modelling can reduce both false positive and false negative results.
Comparison with Traditional Methods
| Assessment Method | Sensitivity Range | Specificity Range | Key Advantages |
|---|---|---|---|
| CA-125 alone | 65–85% | 85–95% | Widely available, established |
| HE4 alone | 70–90% | 90–95% | Less affected by benign conditions |
| ROMA Algorithm | 85–95% | 90–98% | Combines multiple markers |
Note: Sensitivity and specificity figures in the table above represent ranges reported across published peer-reviewed studies and may vary based on study population, laboratory methodology, and clinical context. They should not be interpreted as guaranteed performance figures for any individual test.
Practical Insight: While ROMA shows promising accuracy improvements, it works best when integrated with comprehensive clinical assessment rather than as a standalone diagnostic tool.
Who Should Consider ROMA Algorithm Testing?
Healthcare professionals might suggest ROMA algorithm assessment for individuals who have detected pelvic masses requiring further evaluation, experience persistent abdominal symptoms warranting investigation, present with elevated individual tumour markers requiring clarification, or need risk stratification before surgical planning.
While ROMA can provide valuable insights across age groups, its application may be particularly relevant for post-menopausal individuals (where hormonal changes affect biomarker interpretation), those with family history concerns seeking proactive health monitoring, and individuals with previous ovarian health issues requiring ongoing assessment.
Practical Insight: ROMA testing works best as part of comprehensive health assessment rather than routine screening for asymptomatic individuals. Read more about CA-125 ovarian cancer marker testing to understand how individual biomarkers compare to the combined ROMA approach.
Understanding ROMA Results
Score Interpretation Guidelines
ROMA generates percentage scores interpreted using established threshold values:
- Pre-menopausal: Low risk <11.4%, High risk ≥11.4%
- Post-menopausal: Low risk <29.9%, High risk ≥29.9%
Result Limitations
It’s important to understand that ROMA scores represent statistical probabilities rather than definitive diagnoses. Factors that may influence accuracy include recent hormonal changes, concurrent medical conditions, medication effects, and laboratory variations.
Practical Insight: ROMA results provide valuable guidance but should always be interpreted within the broader context of clinical assessment and individual health circumstances.
ROMA Algorithm vs. Other Assessment Methods
| Method | Advantages | Limitations |
|---|---|---|
| Clinical examination | Direct assessment, immediate availability | Subjective interpretation, limited sensitivity |
| CA-125 testing | Well-established, cost-effective | Elevated in benign conditions |
| HE4 testing | Less affected by inflammation | Limited standalone accuracy |
| ROMA algorithm | Enhanced sensitivity, reduced false positives | Requires both biomarkers, more complex |
| Imaging studies | Visual confirmation, structural detail | Resource intensive, specialist interpretation required |
Frequently Asked Questions
What exactly does the ROMA algorithm measure?
The ROMA algorithm combines CA-125 and HE4 tumour marker levels with menopausal status to calculate a risk percentage for ovarian malignancy, providing a more comprehensive assessment than individual biomarkers alone.
How accurate is ROMA algorithm testing compared to other methods?
Research suggests ROMA may achieve 85–95% sensitivity and 90–98% specificity, representing improvements over individual biomarker assessments. However, accuracy varies based on individual circumstances and clinical context.
Can ROMA algorithm results change over time?
Yes, ROMA scores may fluctuate based on hormonal changes, health status, medications, and other factors. This is why healthcare professionals often recommend repeat testing when clinical circumstances change.
Is ROMA testing suitable for routine ovarian cancer screening?
ROMA is primarily designed for risk assessment in individuals with symptoms or detected masses rather than routine screening for asymptomatic individuals. Healthcare professionals can advise on appropriate testing strategies.
How does menopause affect ROMA algorithm calculations?
The algorithm uses different mathematical formulas and threshold values for pre- and post-menopausal individuals, recognising that hormonal status significantly affects biomarker interpretation.
What happens if my ROMA score indicates high risk?
High-risk ROMA scores typically warrant specialist assessment, additional investigations, and enhanced monitoring. Your healthcare professional can discuss appropriate next steps based on your individual circumstances.
What factors might affect ROMA algorithm accuracy?
Pregnancy, menstruation, certain medications, kidney disease, and other medical conditions may influence biomarker levels and potentially affect ROMA score interpretation.
How long does it take to receive ROMA algorithm results?
Most laboratories can provide ROMA results within 3–5 working days, as the calculation requires processing of both CA-125 and HE4 biomarkers before applying the algorithm formula.
Supporting Your Health Journey
Understanding the ROMA algorithm empowers individuals to engage meaningfully with healthcare professionals about ovarian health assessment options. This sophisticated analytical approach represents one of several tools available for comprehensive health evaluation.
The integration of advanced analytical methods like ROMA with traditional clinical assessment demonstrates how modern healthcare continues evolving to provide increasingly precise and personalised health insights. For women seeking broader gynaecological health context, explore our overview of advanced female health panels vs standard tests.
Medical Disclaimer
This article is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual health concerns, symptoms, or test results should always be assessed by an appropriately qualified healthcare professional. The ROMA algorithm and associated testing should only be undertaken following appropriate medical consultation within the context of comprehensive clinical assessment by qualified healthcare professionals.
Health screening and diagnostic testing services in England are regulated activities. Ensure that any provider you use holds the appropriate Care Quality Commission (CQC) registration for the services they deliver.
Written Date: 6th June 2026 | Next Review Date: 6th June 2027